Supercharged immune cells take on stomach cancer in the belly
NCT ID NCT07509008
First seen Apr 23, 2026 · Last updated Jun 22, 2026 · Updated 11 times
Summary
This early-phase trial tests a new treatment for stomach cancer that has spread to the lining of the abdomen. Ten adults will receive specially engineered natural killer (NK) cells directly into their belly, along with chemotherapy, to see if it is safe and what dose works best. The goal is to find a way to control this hard-to-treat cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER, METASTATIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT MD Anderson
Houston, Texas, 77030, United States
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Engineered natural killer (NK) cells (TROP2 CAR/IL-15 TGFBR2 KO NK cells) given as an infusion into the abdomen, along with chemotherapy drugs (fludarabine, cyclophosphamide) and rimiducid.
What this could lead to
If it works, this could point toward a new treatment option for stomach cancer that has spread to the lining of the abdomen, a condition with very few effective therapies.
What could go wrong
This is a very early, small trial with only 10 participants, focused on safety and dosing. The treatment may not shrink tumors or improve survival, and there are risks from the cell infusion and chemotherapy, such as infection or organ damage.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.